99 related articles for article (PubMed ID: 29676467)
41. Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications.
Hasan SK; Sazawal S; Dutta P; Pillai LS; Kumar B; Chaubey R; Kumar R; Saxena R
Hematology; 2007 Apr; 12(2):99-101. PubMed ID: 17454189
[TBL] [Abstract][Full Text] [Related]
42. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
[TBL] [Abstract][Full Text] [Related]
43. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
44. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
45. [Expression of FLT3 internal tandem duplication in pediatric patients with acute myeloid leukemia and its correlation with multidrug resistance].
Zhao JN; Qiao ZH; Xu LR; Lu QY; Niu XQ; Zhang P; Wang Z
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):23-6. PubMed ID: 19236740
[TBL] [Abstract][Full Text] [Related]
46. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
47. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
48. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
Wang YG; Liu XH; Liang Y; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review.
Beitinjaneh A; Jang S; Roukoz H; Majhail NS
Leuk Res; 2010 Jul; 34(7):831-6. PubMed ID: 20096459
[TBL] [Abstract][Full Text] [Related]
50. FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia.
Mukda E; Pintaraks K; Sawangpanich R; Wiangnon S; Pakakasama S
Asian Pac J Cancer Prev; 2011; 12(7):1827-31. PubMed ID: 22126574
[TBL] [Abstract][Full Text] [Related]
51. NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective.
Sazawal S; Singh N; Jain S; Chhikara S; Chaubey R; Bhattacharyya J; Saikia KK; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2017; 60(3):355-359. PubMed ID: 28937371
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with flt3 mutational status.
Marasca R; Maffei R; Zucchini P; Castelli I; Saviola A; Martinelli S; Ferrari A; Fontana M; Ravanetti S; Torelli G
Leukemia; 2006 Jan; 20(1):103-14. PubMed ID: 16270043
[TBL] [Abstract][Full Text] [Related]
53. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
[TBL] [Abstract][Full Text] [Related]
54. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
[TBL] [Abstract][Full Text] [Related]
55. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
56. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
[TBL] [Abstract][Full Text] [Related]
57. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
58. FLT3-ITD Mutations in Egyptian Patients of Acute Myeloid Leukemia: Correlation with Cytogenetic, FAB Subgroups and Prognosis.
Adnan-Awad S; Gaber O; Eltokhy SA; Mourad D; Amer M; Kandeel EZ; Eldesouky I
Clin Lab; 2017 May; 63(5):1027-1034. PubMed ID: 28627830
[TBL] [Abstract][Full Text] [Related]
59. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
60. Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin.
Ottone T; Zaza S; Divona M; Hasan SK; Lavorgna S; Laterza S; Cicconi L; Panetta P; Di Giandomenico J; Cittadini M; Ciardi C; Montefusco E; Franchi A; Annino L; Venditti A; Amadori S; Lo-Coco F
Br J Haematol; 2013 May; 161(4):533-40. PubMed ID: 23480665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
